These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10220611)

  • 21. [Primary health care costs in connection with heart failure surveyed: increased use of ACE inhibitors would be beneficial].
    Malmberg I; Persson U
    Lakartidningen; 2000 May; 97(20):2465-70. PubMed ID: 10909223
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Economical treatment of heart failure].
    Sonntag F
    Med Klin (Munich); 1996 Feb; 91(2):111. PubMed ID: 8850107
    [No Abstract]   [Full Text] [Related]  

  • 24. Economics of treating heart failure.
    Mark DB
    Am J Cardiol; 1997 Oct; 80(8B):33H-38H. PubMed ID: 9372996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE inhibitors: current understanding and future directions.
    Cleland JG
    Br Heart J; 1994 Sep; 72(3 Suppl):S1. PubMed ID: 7946794
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness analysis in clinical practice: the case of heart failure.
    Rich MW; Nease RF
    Arch Intern Med; 1999 Aug 9-23; 159(15):1690-700. PubMed ID: 10448770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Added organ protection at little cost. Double savings with ACE inhibitors].
    MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725008
    [No Abstract]   [Full Text] [Related]  

  • 30. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
    Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
    Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACE inhibitors and health-care economics.
    Davie AP; McMurray JJ
    Coron Artery Dis; 1995 Apr; 6(4):315-9. PubMed ID: 7655715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The economics of heart failure.
    Kazi DS; Mark DB
    Heart Fail Clin; 2013 Jan; 9(1):93-106. PubMed ID: 23168320
    [No Abstract]   [Full Text] [Related]  

  • 34. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of the clinical pathway in the management of congestive heart failure.
    Ranjan A; Tarigopula L; Srivastava RK; Obasanjo OO; Obah E
    South Med J; 2003 Jul; 96(7):661-3. PubMed ID: 12940315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
    Paul SD; Kuntz KM; Eagle KA; Weinstein MC
    Arch Intern Med; 1994 May; 154(10):1143-9. PubMed ID: 8185426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.
    Hart WM; Rubio-Terres C; Pajuelo F; González Juanatey JR
    Eur J Heart Fail; 2002 Aug; 4(4):553-8. PubMed ID: 12167396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
    Taylor M; Scuffham PA; Chaplin S; Papo NL
    Value Health; 2009 Jun; 12(4):459-65. PubMed ID: 19192258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.